Key Highlights

  • RF Acquisition Corp II shares rallied about 7.6%, with no single new announcement clearly tied to the move.
  • The company has a signed agreement to merge with Singapore-based Nanyang Biologics at an implied Equity value of $1.5 billion.
  • Roughly $71.58 million was redeemed from the trust account, leaving about $51.86 million in trust as of the latest filing.
  • In a no-redemption scenario, target shareholders would own roughly 94% of the combined company, with RFAC public shareholders holding about 4%.

Shares of RF Acquisition Corp II (NASDAQ:RFAI) rallied about 7.6% in August 2026 as traders positioned around the special-purpose acquisition company's pending $1.5 billion merger. No single new announcement was clearly tied to the move, but a defined deal and an approaching Shareholder vote give the stock a catalyst framework that SPAC traders watch closely.

Why the Stock Is Surging

The exact trigger for RFAI's latest gain is not clearly established in public sources. SPAC common shares often trade in a narrow band near their trust value and then move on deal developments, Redemption dynamics, and speculation ahead of a Merger vote. RFAI fits that profile: it has a signed Business combination and is advancing through the regulatory process.

Because the announced deal, a merger with Singapore-based Nanyang Biologics valued at roughly $1.5 billion, carries a high headline value relative to RFAI's small trust, the stock can attract speculative interest as the transaction moves toward completion. Absent a specific press release timed to the move, that anticipation, rather than a confirmed new catalyst, is the most likely explanation.

What Happened

RF Acquisition Corp II is a Cayman Islands blank-check company that agreed on October 2, 2025, to combine with NYB Holdings Limited and Nanyang Biologics Pte. Ltd. Under the structure, RFAC would merge into a new public company (PubCo), with Nanyang Biologics becoming a wholly owned subsidiary. The combined company intends to list under the ticker "NYB."

According to an amended Form F-4/A registration statement dated April 17, 2026, the deal implies an equity value of $1.5 billion at $10.00 per share and contemplates issuing up to about 158.9 million PubCo ordinary shares. In a no-redemption scenario, target shareholders would own roughly 94% of the combined company, RFAC public shareholders about 4%, and the sponsor and affiliates about 2%.

The filing also showed the effects of redemptions: approximately $71.58 million was redeemed from the trust account at about $10.73 per share, leaving roughly $51.86 million in trust as of the filing. The company previously held a shareholder extension vote on November 10, 2025, and an extraordinary general meeting to approve the combination was scheduled for 2026.

Why Investors Are Paying Attention

SPAC deals involving overseas targets and large headline valuations frequently draw trader interest, especially as a merger vote nears. RFAI's transaction has been publicized as a roughly $1.5 billion AI-biotech combination linked to The9's Singapore investee, which adds a thematic hook to the story.

The gap between RFAI's small remaining trust, under $52 million after redemptions, and the $1.5 billion headline value of the target is the kind of setup that can produce Volatility once the deal closes and the share count and float are established. Traders often try to anticipate that dynamic, contributing to pre-vote price swings.

What the Company Does

RF Acquisition Corp II is a blank-check company, meaning it has no commercial operations of its own. It was formed to raise Capital through an IPO and then merge with or acquire an operating business, giving that business a public listing.

Its merger target, Nanyang Biologics, is identified in SEC filings as operating in the biologics sector. Detailed operational and product information was not spelled out in the amendment reviewed, so investors evaluating the deal should rely on the full F-4 registration statement and related disclosures for specifics on the target's business, pipeline and financial condition.

Bull Case

For SPAC arbitrage-oriented investors, the bull case is structural: holders who bought near trust value have historically had downside protection from redemption rights, while retaining upside if the combined company trades well after closing. RFAI's shares have traded around trust levels, and the pending deal provides a defined path to a completed listing.

For those bullish on the target, the appeal is exposure to a Singapore-based biologics company entering U.S. public markets at a $1.5 billion implied valuation, with the potential for a re-rating if Nanyang Biologics executes. The prospect of a large, thematically resonant biotech listing is what keeps speculative traders engaged.

Risks

SPAC combinations carry well-known risks. Deals can be delayed, renegotiated or terminated, and shareholder votes are not guaranteed to pass. Heavy redemptions, already significant here, with more than $71 million pulled from trust, can leave the combined company with limited cash, pressuring its Balance Sheet post-merger.

Because target shareholders would own roughly 94% of the combined entity, the public float could be small and volatile after closing, a common source of sharp swings in de-SPAC stocks. Investors should also weigh the limited operational disclosure on Nanyang Biologics available in the reviewed amendment and the general execution risk of a clinical or early-stage biologics business. A pre-deal rally can reverse quickly if the transaction stumbles.

What Investors Should Watch Next

  • The scheduled date and outcome of the extraordinary general meeting to approve the business combination.
  • Additional redemption activity and the amount of cash remaining in trust at closing.
  • Updated F-4 disclosures detailing Nanyang Biologics' business, financials and pipeline.
  • Confirmation of the "NYB" ticker listing and the post-close share count and float.
  • Any amendments, extensions or changes to the deal terms or timeline.

Trading Ahead of an Unresolved Vote

RFAI's roughly 7.6% rally reflects trader positioning around a defined but not-yet-completed SPAC merger rather than a confirmed new catalyst. The company has a signed $1.5 billion combination with Singapore's Nanyang Biologics, an approaching shareholder vote, and a small, redemption-reduced trust, a mix that can generate volatility as the deal progresses. Prospective buyers should focus on the vote timeline, redemption levels and the target's disclosures, and remain mindful that de-SPAC situations can move violently in both directions once a merger closes.